Thanks for the chart of possible uses for rATIII in different acquired deficiences. When the partnership finally does materialize, I would like to see them fully fund trials in one or more of them. The point is we need to expand rATIII past only sepsis since I don't know if GTCB could survive if the sepsis news is bad.